A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASP8062 with a Single Dose of Morphine in Recreational Opioid Using Participants

Trial Identifier: 8062-CL-2002
Sponsor: Astellas Pharma Global Development, Inc.
Collaborator:
National Institute on Drug Abuse
Start Date: June 2020
Primary Completion Date: September 2020
Study Completion Date: September 2020

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description

Trial Locations

Country Location
United States of America, KS Overland Park, KS, United States of America, 66212